These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30790150)

  • 41. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J; Wang W; Lin J; Chen R; Cao Y
    J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
    Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
    Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
    Takeuchi K; Togashi Y; Kamihara Y; Fukuyama T; Yoshioka H; Inoue A; Katsuki H; Kiura K; Nakagawa K; Seto T; Maemondo M; Hida T; Harada M; Ohe Y; Nogami N; Yamamoto N; Nishio M; Tamura T
    Ann Oncol; 2016 Jan; 27(1):185-92. PubMed ID: 26487585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
    Kathuria-Prakash N; Lopez LP; Raman S; Ye H; Anaokar J; Sisk A; Pantuck AJ; Drakaki A
    JCO Precis Oncol; 2024 Jun; 8():e2400154. PubMed ID: 38885453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V; Ou SH
    Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
    Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
    Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
    Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
    Ajimizu H; Kim YH; Mishima M
    Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
    Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
    BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
    Chino H; Sekine A; Kitamura H; Kato T; Ogura T
    Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation.
    Usmani S; Marafi F; Rasheed R; Al Maraghy M; Al Kandari F
    Clin Nucl Med; 2018 Oct; 43(10):752-754. PubMed ID: 30059431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
    Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
    Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.